Showing 3931-3940 of 9076 results for "".
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://practicaldermatology.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- Study Links MRGPRX3 Expression to Chronic Pruritus in PN and ADhttps://practicaldermatology.com/news/study-links-mrgprx3-expression-to-chronic-pruritus-in-pn-and-ad/2486413/In a prospective analysis of skin biopsies, investigators reported significantly elevated cutaneous MRGPRX3 expression in lesional prurigo nodularis (PN) and atopic dermatitis (AD), alongside a notable association between MRGPRX3-related gene mutations and Black pa
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://practicaldermatology.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot